Level D· Scientific groundwork from lab and animal studiesNarrative ReviewEurope PMCOpen access

Long non-coding RNAs as molecular links and circulating biomarkers between type 2 diabetes and colorectal cancer: focus on shared signaling pathways, epigenetic regulation, and ubiquitination mechanisms

Wu L., Meng Q., Zhou Y.

Narrative Review on Type 2 Diabetes, Cardiovascular Disease, published in Front Mol Biosci (2026) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Narrative Review
Journal
Front Mol Biosci (2026)
Reported sample size
—
Source database
Europe PMC
PMID
42256316
PMCID
PMC13233395
DOI
10.3389/fmolb.2026.1775065

Abstract (original English)

Type 2 Diabetes (T2D) and Colorectal Cancer (CRC) share a complex bidirectional relationship driven by common metabolic and inflammatory pathways. This review comprehensively examines the pivotal role of Long Non-Coding RNAs (lncRNAs) as molecular bridges between T2D and CRC, regulating gene expression at chromatin, transcriptional, and post-transcriptional levels. We focus on specific lncRNAs including H19, ANRIL, KCNQ1OT1, UCA1, GAS5, MIR31HG, HNF1A-AS1, and MALAT1, which modulate shared oncogenic and metabolic signaling cascades such as PI3K/AKT, Wnt/β-catenin, NF-κB, and HIF-1α. Furthermore, we expand the scope beyond isolated lncRNA regulation to emphasize the lncRNA-miRNA crosstalk and the systemic involvement of the cardiovascular system. Recent evidence highlights that miR-217, miR-122, and the NBAT1/miR-21 axis are critical regulators not only in CRC progression but also in myocardial injury associated with T2D. Consequently, we propose that a holistic biomarker strategy must integrate panels of both lncRNAs and miRNAs to capture the full spectrum of metabolic, oncogenic, and cardiac risks. This updated perspective underscores the translational potential of targeting multi-ncRNA networks for early diagnosis, prognosis, and therapeutic intervention in patients with multimorbidity.

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is a narrative review: it collects no new patient data and does not systematically appraise evidence quality.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research